109 Episodes

  1. The HER2 Diagnostic and Treatment Landscape in NSCLC

    Published: 4/29/2025

  2. Overview of Biliary Tract Cancer & Importance of Targeted Therapies

    Published: 4/24/2025

  3. What does it mean to be HER2 Positive in Lung Cancer

    Published: 4/21/2025

  4. European Lung Cancer Conference (ELCC) 2025 Highlights: KEYNOTE-799, LAURA, MARIPOSA, KRYSTAL-7

    Published: 4/14/2025

  5. FDA Approval of Cabozantinib - CABINET in pNET and epNET

    Published: 4/10/2025

  6. How to Manage & Treat Pancreatic Cancer

    Published: 4/7/2025

  7. How to Treat Upper Gastrointestinal Cancers in 2025 - Treatment Algorithm

    Published: 3/31/2025

  8. ToxCheck: Managing Side Effects of Pancreatic Cancer Treatment

    Published: 3/27/2025

  9. Prostate Cancer Management from Early Stage to Advanced Metastatic Disease - Dr. Alan Bryce

    Published: 3/24/2025

  10. How to Treat Renal Cell Carcinoma (RCC) using a Treatment Algorithm with Dr. Katy Beckermann

    Published: 3/17/2025

  11. How to Treat Bladder Cancer in 2025 with Dr. Joaquim Bellmunt

    Published: 3/10/2025

  12. FDA Approval of Tislelizumab - RATIONALE 305 and 306 in Upper GI Cancers

    Published: 3/6/2025

  13. GU ASCO 2025 Highlights - TALAPRO-2, NIAGARA, CheckMate-9ER, TiNivo-2

    Published: 3/3/2025

  14. How to Treat Hormone Receptor Positive Cancer - Latest Advancements and Current Standard of Care in 2025

    Published: 2/24/2025

  15. FDA Approval of Zolbetuximab SPOTLIGHT / GLOW study - Upper GI Cancer with Claudin 18.2 Mutation

    Published: 2/21/2025

  16. How to Treat HER2+ Breast Cancer - Discussion with Dr. Sarah Sammons

    Published: 2/17/2025

  17. How to Treat Triple Negative Breast Cancer - Discussion with Dr. Virginia Kaklamani

    Published: 2/10/2025

  18. GI ASCO 2025 Highlights - BREAKWATER, CheckMate-8HW, ALASCCA, STARTER-NET

    Published: 2/3/2025

  19. FDA Approval of Subcutaneous Nivolumab CheckMate-67T - Subcutaneous Nivo vs. Intravenous (IV) Nivo

    Published: 1/31/2025

  20. Intermediate HCC – the evolving role of Immunotherapy with Multimodality approaches

    Published: 1/27/2025

1 / 6

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at [email protected]